Non-rebreather mask and low-flow nasal cannula vs high-flow nasal cannula in severe COVID-19 pneumonia in the emergency department.
COVID-19
High-flow nasal cannula
Hypoxemic respiratory failure
Non-rebreather mask
Oxygen therapy
Journal
The American journal of emergency medicine
ISSN: 1532-8171
Titre abrégé: Am J Emerg Med
Pays: United States
ID NLM: 8309942
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
05
04
2022
revised:
06
10
2022
accepted:
11
10
2022
pubmed:
4
11
2022
medline:
15
12
2022
entrez:
3
11
2022
Statut:
ppublish
Résumé
To assess the effectiveness of non-rebreather mask combined with low-flow nasal cannula (NRB + NC) compared to high-flow nasal cannula (HFNC) in improving oxygenation in patients with COVID-19-related hypoxemic respiratory failure (HRF). This retrospective study was conducted in emergency departments of two tertiary hospitals from June 1 to August 31, 2021. Consecutive patients aged >18 years admitted for COVID-19-related HRF (World Health Organization criteria: confirmed COVID-19 pneumonia with respiratory rate > 30 breaths/min, severe respiratory distress, or peripheral oxygen saturation < 90% on room air) requiring NRB + NC or HFNC were screened for enrollment. Primary outcome was improvement of partial pressure arterial oxygen (PaO Among the 110 patients recruited, 52 (47.3%) were treated with NRB + NC, and 58 (52.7%) with HFNC. There were significant improvements in patients' PaO HFNC may be beneficial in COVID-19 HRF. NRB + NC is a viable alternative, especially in resource-limited settings, given similar improvement in oxygenation at two hours, and no significant differences in long-term outcomes. The effectiveness of NRB + NC needs to be investigated by a powered randomized controlled trial.
Sections du résumé
BACKGROUND
To assess the effectiveness of non-rebreather mask combined with low-flow nasal cannula (NRB + NC) compared to high-flow nasal cannula (HFNC) in improving oxygenation in patients with COVID-19-related hypoxemic respiratory failure (HRF).
METHODS
This retrospective study was conducted in emergency departments of two tertiary hospitals from June 1 to August 31, 2021. Consecutive patients aged >18 years admitted for COVID-19-related HRF (World Health Organization criteria: confirmed COVID-19 pneumonia with respiratory rate > 30 breaths/min, severe respiratory distress, or peripheral oxygen saturation < 90% on room air) requiring NRB + NC or HFNC were screened for enrollment. Primary outcome was improvement of partial pressure arterial oxygen (PaO
RESULTS
Among the 110 patients recruited, 52 (47.3%) were treated with NRB + NC, and 58 (52.7%) with HFNC. There were significant improvements in patients' PaO
CONCLUSION
HFNC may be beneficial in COVID-19 HRF. NRB + NC is a viable alternative, especially in resource-limited settings, given similar improvement in oxygenation at two hours, and no significant differences in long-term outcomes. The effectiveness of NRB + NC needs to be investigated by a powered randomized controlled trial.
Identifiants
pubmed: 36327755
pii: S0735-6757(22)00651-9
doi: 10.1016/j.ajem.2022.10.029
pmc: PMC9578968
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-93Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
JAMA. 2021 Dec 07;326(21):2161-2171
pubmed: 34874419
Respir Care. 2020 Mar;65(3):369-376
pubmed: 31744865
Ann Intensive Care. 2021 Feb 27;11(1):37
pubmed: 33638752
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
BMC Pulm Med. 2017 Nov 17;17(1):142
pubmed: 29149868
Intensive Care Med. 2019 May;45(5):563-572
pubmed: 30888444
Anaesth Intensive Care. 2011 Nov;39(6):1103-10
pubmed: 22165366
Med J Aust. 2020 Jun;212(10):472-481
pubmed: 32356900
Ann Intensive Care. 2020 Jun 9;10(1):78
pubmed: 32519064
Eur Respir J. 2020 Nov 5;56(5):
pubmed: 32747398
Am J Emerg Med. 2020 Oct;38(10):2160-2168
pubmed: 33046288
Intensive Care Med. 2020 Nov;46(11):2094-2095
pubmed: 32737522
Respir Med. 2016 Dec;121:100-108
pubmed: 27888983
Crit Care Med. 2021 Mar 1;49(3):e219-e234
pubmed: 33555780
JAMA. 2021 May 4;325(17):1731-1743
pubmed: 33764378
Trials. 2020 Jan 14;21(1):81
pubmed: 31937322
JAMA. 2022 Feb 8;327(6):546-558
pubmed: 35072713
Pulmonology. 2021 Jul-Aug;27(4):305-312
pubmed: 33516668
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958